PSCH Fact Sheet: Invesco S&P SmallCap Health Care ETF
Share
$56.12
close, Nov 18, 2026
Over the year to Nov 18, 2026, PSCH returned +33.8% in total and charged 0.29% a year.
- 1-year total return
- +33.8%
- to Nov 18, 2026
- Expense ratio
- 0.29%
- a year
- Net assets
- $186m
- on Nov 17, 2026
- Net flow, last 5 trading days
- +$5.1m
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
PSCH $13,375 +33.8% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+6.9%
3 months−0.2%
Year to date+27.4%
1 year+33.8%
3 years+50.3%
5 years−7.4%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
TG Therapeutics Inc4.89%
Protagonist Therapeutics Inc4.44%
Alkermes PLC4.19%
Teleflex Inc3.73%
Supernus Inc3.31%
Ligand Pharmaceuticals Inc3.22%
RadNet Inc2.92%
Merit Medical Systems Inc2.77%
PTC Therapeutics Inc2.77%
Concentra Group Holdings Parent Inc2.76%
PSCH top ten by weight, 35.0% of the fund, of its 69 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the S&P SmallCap 600 Capped Health Care Index · First traded Apr 7, 2010 · Benchmark Its own holdings, as of Nov 17, 2026